Advertisement

Topics

NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis

06:37 EDT 6 Jun 2017 | PharmaTimes

Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.

Original Article: NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis

NEXT ARTICLE

More From BioPortfolio on "NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...